Shareprice
18 Apr 2024

Press & news

FluoGuide develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system.

New - New exchange: Nasdaq First North

FluoGuide is moving from Spotlight to Nasdaq First North. Shareholders are strongly encouraged to make sure they will be able to freely trade their shares in the future.

SEB initiates commissioned research on FluoGuide

Press release


November 30, 2020

Copenhagen, Denmark, 30 November 2020 – FluoGuide A/S (“FluoGuide” or the “Company”) has entered into an agreement with Skandinaviska Enskilda Banken (“SEB”) on commissioned research coverage.

Starting today, SEB will initiate its commissioned research, meaning that SEB will continuously monitor and analyze FluoGuide’s operations, its products, markets, and competitors.

The initial research report is available here.

FluoGuide A/S is obliged to publish this information in accordance with the EU Market Abuse Regulation. The information was provided by the contact person set out above for publication on 30 November 2020.